News

June 22, 2017June 22, 2017

Supplemental Oxygen Improves Exercise Endurance in IPF Patients, Study Finds

Supplemental oxygen enhances exercise endurance and reduces breathing difficulties in patients with idiopathic pulmonary fibrosis (IPF), an Australian study shows. The study, “Greater endurance capacity and improved dyspnoea with acute ... Read more

June 21, 2017June 21, 2017

Severe Asthma Still Under-recognized and Uncontrolled, According to New European Study

Asthma, News

A new European study suggests that a large percentage of patients (94 percent in this study) suffering from severe asthma still struggle with the burden of uncontrolled disease. The data, ... Read more

June 20, 2017June 20, 2017

Baseball Star Bernie Williams Helps Pulmonary Fibrosis Foundation Boost Federal Funding

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) has enlisted former New York Yankees baseball champion Bernie Williams to help lobby U.S. lawmakers for more federal funds to develop safe and effective therapies for an incurable ... Read more

June 19, 2017June 19, 2017

Australian Pulmonary Fibrosis Registry Offers Real-world Insight Into the Disease

Idiopathic Pulmonary Fibrosis, News

Patients in the Australian Idiopathic Pulmonary Fibrosis Registry who take anti-fibrotic therapies tend to live longer than those who do not, according to an analysis of the records. Another finding ... Read more

June 16, 2017June 16, 2017

Baseball Legend Bernie Williams Joins IPF Awareness Campaign

Idiopathic Pulmonary Fibrosis, News

New York Yankees legend Bernie Williams is honoring his father by joining the Sin Aliento campaign to encourage people who may have idiopathic pulmonary fibrosis (IPF) to seek early diagnosis and treatment. Williams’ ... Read more

June 15, 2017June 15, 2017

Pulmatrix Strikes Licensing Deal to Gain Access to RespiVert’s Lung Disease Treatments

Idiopathic Pulmonary Fibrosis, News

Pulmatrix has signed a licensing agreement with RespiVert, a subsidiary of Janssen Biotech, to gain access to RespiVert’s portfolio of kinase inhibitors for treating lung diseases. Kinase inhibitors act by blocking ... Read more

June 14, 2017June 14, 2017

PETA Science Consortium Gives Vitrocell’s Animal-free Test Equipment to Labs in US and Europe

Idiopathic Pulmonary Fibrosis, News

PETA’s International Science Consortium (PISC) is donating $400,000 worth of Vitrocell animal-free inhalation test equipment to four institutions in the United States and Europe. PISC promotes non-animal research methods and coordinates the scientific ... Read more

June 13, 2017June 13, 2017

Orkambi Improves Lung Function of Children with Cystic Fibrosis, Update of Trial Results Indicates

Cystic Fibrosis, News

Vertex Pharmaceuticals‘ Orkambi significantly improved the lung function of children with cystic fibrosis, compared with a placebo, according to updated Phase 3 clinical trial results. An update of another Phase 3 trial’s ... Read more

June 12, 2017June 12, 2017

Canadian Lung Cancer Groups Call for Speedy Public Funding of New Therapies

Lung Cancer, News

Two Canadian lung cancer organizations have asked provincial government officials and the pharmaceutical industry to expedite negotiations that lead to the public funding of several new Health Canada-approved treatments. Lung Cancer ... Read more

June 8, 2017June 8, 2017

Lung Therapeutics Announces $14.3 Million in Funding to Continue Research on Potential Disease Therapies

Idiopathic Pulmonary Fibrosis, News

Lung Therapeutics, which specializes in therapies for fibrosis, lung injury and lung disease, announced that it has raised $14.3 million in Series B financing. The funding will support ongoing clinical trials in Australia ... Read more